**
In a significant development for Canadian healthcare, Apotex Inc., the country’s leading pharmaceutical manufacturer, has received the green light from Health Canada to distribute a generic version of Ozempic, a highly sought-after medication for diabetes management. This approval follows closely on the heels of a similar endorsement granted to Dr. Reddy’s Laboratories Ltd., an Indian firm, earlier this week, making Apotex the first Canadian company to enter this competitive market. The launch of generic semaglutide is expected to enhance accessibility and affordability for Canadian patients battling Type 2 diabetes.
A Game-Changer for Diabetes Treatment
Apotex’s president for Canada and global markets, Martin Arès, announced that the generic semaglutide product is anticipated to hit pharmacy shelves within weeks. “We’re very dedicated to bringing these affordable solutions to Canadians as soon as possible,” Arès stated, indicating the company’s commitment to improving healthcare access.
Ozempic, manufactured by Danish pharmaceutical giant Novo Nordisk, has become the top-selling drug in Canada, generating an impressive $2.9 billion in sales in 2025. Its rising popularity is attributed to its efficacy in managing blood sugar levels, with over one million Canadians currently relying on the drug. The introduction of generic alternatives is expected to further increase usage, particularly as broader access comes into play.
The Pricing Landscape
In Canada, the pricing of generic medications is governed by a framework established by the pan-Canadian Pharmaceutical Alliance, which ensures that the introduction of generics leads to significant cost reductions. When two generic products are available, the price must be set at half of the brand-name counterpart, decreasing further to 35% once there are three or more options on the market. Given the current list price for a four-week supply of Ozempic is $228, this pricing model promises substantial savings for Canadian consumers.
Furthermore, Apotex has received tentative approval from the U.S. Food and Drug Administration (FDA) for their generic semaglutide, developed in collaboration with Indian pharmaceutical company Orbicular Pharmaceutical Technologies. However, this approval is contingent on the expiration of existing legal protections, with the primary U.S. patent on Ozempic not set to expire until 2032.
Production and Future Prospects
Despite being Canada’s largest drug manufacturer, Apotex will not produce semaglutide domestically due to the specialised manufacturing processes required. Arès has not disclosed the production location, but the firm remains focused on ensuring a timely launch. The Health Canada-approved version of semaglutide is specifically indicated for treating Type 2 diabetes, though the company has yet to confirm any intentions to seek approval for other indications, such as weight management.
The landscape for generics typically results in public drug plans ceasing reimbursement for brand-name medications in favour of more affordable alternatives. This transition is expected to be seamless for Ozempic in diabetes care, but there may be complexities surrounding the reimbursement of Wegovy, the higher-dose counterpart aimed at chronic weight management, which has not yet been listed by public drug plans.
Implications for Patients and Healthcare
Sanjeev Sockalingam, scientific director at Obesity Canada, expressed hope that the arrival of cheaper generics will encourage both public and private insurance plans to cover semaglutide for weight management. “For many patients, cost continues to be a limiting factor,” he remarked, underscoring the financial barriers that many Canadians face in accessing effective treatments.
Public drug plans across Canada already cover brand-name Ozempic for diabetes management, having collectively spent $794.1 million on the drug in 2024, a significant increase from $130.5 million in 2020. However, Wegovy remains outside the purview of public funding, leaving a gap in coverage for those seeking weight-loss treatment.
As private insurance companies grapple with rising prescription costs, the introduction of generic semaglutide could lead to substantial savings for both insurers and patients. According to a recent TELUS Health report, private insurers spent more on diabetes-related medications and devices in 2025 than on any other health condition, with Ozempic accounting for nearly 40% of that expenditure.
Why it Matters
The approval of Apotex’s generic semaglutide is more than just a regulatory milestone; it represents a monumental shift in the accessibility of diabetes treatments in Canada. With an increasing number of Canadians diagnosed with Type 2 diabetes, the arrival of affordable alternatives like generic Ozempic could help alleviate the financial burden on patients and healthcare systems alike. As competition in the market heats up, the potential for reduced prices and improved access to essential medications is a promising development for the future of Canadian healthcare.
